Equillium Inc (EQ)

$2.21 -0.01 (-0.45%)
Market Cap 140.13M
Revenue (ttm) 0.00
Net Income (ttm) -22.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 225,900
Avg Vol 679,154
Day's Range N/A - N/A
Shares Out 63.41M
Stochastic %K 16%
Beta 1.81
Analysts Strong Sell
Price Target $8.60

Company Profile

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as At...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 240 1200
Address:
2223 Avenida De La Playa, Suite 105, La Jolla, United States
uieriwer
uieriwer Sep. 7 at 1:13 PM
$EQ I know everyone is expecting this to break out, but I'm getting worried it will even survive. What is latest cash flow data?
0 · Reply
LordFawkwadReturns
LordFawkwadReturns Aug. 27 at 8:53 PM
$EQ Hell yeah man doubled my position on that sweet dip
0 · Reply
AC_TRADER
AC_TRADER Aug. 27 at 8:07 PM
$EQ levels are mapped. Now let's see what price does. 👀 Built with @TrendSpider. https://share.trendspider.com/chart/EQ/7594byf17z
0 · Reply
peloswing
peloswing Aug. 27 at 3:20 PM
$EQ is up 12% since our chart @Stocktwits
2 · Reply
peloswing
peloswing Aug. 26 at 5:56 PM
$EQ up >9% already! @Stocktwits
1 · Reply
peloswing
peloswing Aug. 25 at 1:52 PM
Watch $EQ if it can break out here. Average price target is $8.60 (289% above current price). - $20 price target by Piper Sandler - $12 price target by Roth Capital
2 · Reply
peloswing
peloswing Aug. 24 at 1:29 PM
$EQ holding its long rising trendline 📊 The story: lead asset EQ504 (oral AhR modulator for ulcerative colitis) — Phase 1 proof-of-mechanism initiating mid-2026, data ~6 months later. Recent Leerink upgrade + supportive UC data drove the run. 📅 Catalyst calendar = the whole thesis: Phase 1 data readouts are the binary events. Analyst targets: $4 to $20 (avg ~$8.60)
2 · Reply
ADelightfulman
ADelightfulman Aug. 19 at 4:46 PM
$EQ in again! $MRK in the making!
1 · Reply
Orlandotrader
Orlandotrader Aug. 15 at 8:18 PM
$EQ Let’s announce that Phase One already!!
0 · Reply
Orlandotrader
Orlandotrader Aug. 15 at 8:18 PM
$EQ Trying to Form that Bottom.
0 · Reply
Latest News on EQ
Equillium management to meet with Piper Sandler

2026-09-04T19:10:16.000Z - 2 days ago

Equillium management to meet with Piper Sandler

Equillium to Participate in Upcoming Investor Conferences

Sep 2, 2026, 8:30 AM EDT - 5 days ago

Equillium to Participate in Upcoming Investor Conferences

Equillium reports Q2 EPS (4c), consensus (6c)

2026-08-16T14:06:38.000Z - 21 days ago

Equillium reports Q2 EPS (4c), consensus (6c)

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Aug 13, 2026, 4:05 PM EDT - 24 days ago

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Equillium Earnings release: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 24 days ago

Equillium Earnings release: Q2 2026

Equillium Quarterly report: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 24 days ago

Equillium Quarterly report: Q2 2026

Equillium Slides: Corporate presentation

Aug 13, 2026, 7:00 AM EDT - 25 days ago

Equillium Slides: Corporate presentation

Equillium initiated with a Buy at Clear Street

2026-07-21T20:20:14.000Z - 6 weeks ago

Equillium initiated with a Buy at Clear Street

Equillium initiated with an Overweight at Piper Sandler

2026-07-13T08:55:18.000Z - 1 month ago

Equillium initiated with an Overweight at Piper Sandler

EQ Works Expands Multi-Year Partnership with Leading Canadian Publisher to Include SaaS License for ClearLake

Jun 18, 2026, 8:00 AM EDT - 2 months ago

EQ Works Expands Multi-Year Partnership with Leading Canadian Publisher to Include SaaS License for ClearLake

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2026, 4:05 PM EDT - 3 months ago

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equillium to Participate in the 2026 Jefferies Global Healthcare Conference

May 28, 2026, 4:05 PM EDT - 3 months ago

Equillium to Participate in the 2026 Jefferies Global Healthcare Conference

Equillium price target raised to $7 from $6 at Raymond James

2026-05-28T15:03:08.000Z - 3 months ago

Equillium price target raised to $7 from $6 at Raymond James

Leerink upgrades Equillium on ‘supportive’ ulcerative colitis data

2026-05-28T10:33:06.000Z - 3 months ago

Leerink upgrades Equillium on ‘supportive’ ulcerative colitis data

Equillium upgraded to Outperform from Market Perform at Leerink

2026-05-28T10:26:43.000Z - 3 months ago

Equillium upgraded to Outperform from Market Perform at Leerink

Equillium Transcript: Status update

May 27, 2026, 11:00 AM EDT - 3 months ago

Equillium Transcript: Status update

Equillium Slides: Status update

May 27, 2026, 11:00 AM EDT - 3 months ago

Equillium Slides: Status update

Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis

May 20, 2026, 4:05 PM EDT - 3 months ago

Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis

Equillium Slides: Corporate presentation

May 14, 2026, 7:00 AM EDT - 3 months ago

Equillium Slides: Corporate presentation

Equillium reports Q1 EPS (6c), consensus (4c)

2026-05-13T20:28:34.000Z - 3 months ago

Equillium reports Q1 EPS (6c), consensus (4c)

Equillium appoints Snehal Naik as chief development officer

2026-05-13T20:22:18.000Z - 3 months ago

Equillium appoints Snehal Naik as chief development officer

Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights

May 13, 2026, 4:01 PM EDT - 3 months ago

Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights

Equillium Earnings release: Q1 2026

May 13, 2026, 4:00 PM EDT - 3 months ago

Equillium Earnings release: Q1 2026

Equillium Quarterly report: Q1 2026

May 13, 2026, 4:00 PM EDT - 3 months ago

Equillium Quarterly report: Q1 2026

Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events

Apr 28, 2026, 9:30 AM EDT - 4 months ago

Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events

Equillium initiated with an Outperform at Oppenheimer

2026-04-23T10:37:22.000Z - 4 months ago

Equillium initiated with an Outperform at Oppenheimer

Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event

Apr 20, 2026, 4:05 PM EDT - 4 months ago

Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event

Equillium initiated with a Buy at B. Riley

2026-04-16T14:07:26.000Z - 4 months ago

Equillium initiated with a Buy at B. Riley

Equillium Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 4 months ago

Equillium Proxy statement: Proxy filing

Equillium Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 4 months ago

Equillium Proxy statement: Proxy filing

Equillium initiated with a Strong Buy at Raymond James

2026-04-13T20:10:44.000Z - 4 months ago

Equillium initiated with a Strong Buy at Raymond James

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

Apr 8, 2026, 8:30 AM EDT - 5 months ago

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

Equillium files to sell 18.88M shares of common stock for holders

2026-04-07T21:15:15.000Z - 5 months ago

Equillium files to sell 18.88M shares of common stock for holders

Cantor starts Equillium at Overweight on ulcerative colitis potential

2026-04-07T12:01:55.000Z - 5 months ago

Cantor starts Equillium at Overweight on ulcerative colitis potential

Equillium Registration statement: Registration filing

Apr 7, 2026, 8:00 AM EDT - 5 months ago

Equillium Registration statement: Registration filing

Equillium initiated with an Overweight at Cantor Fitzgerald

2026-04-07T10:37:07.000Z - 5 months ago

Equillium initiated with an Overweight at Cantor Fitzgerald

Equillium Proxy statement: Proxy filing

Mar 30, 2026, 8:00 AM EDT - 5 months ago

Equillium Proxy statement: Proxy filing

Equillium Slides: Corporate presentation

Mar 27, 2026, 8:00 AM EDT - 5 months ago

Equillium Slides: Corporate presentation

Equillium reports Q4 EPS (4c), consensus (6c)

2026-03-25T20:21:31.000Z - 5 months ago

Equillium reports Q4 EPS (4c), consensus (6c)

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Mar 25, 2026, 4:05 PM EDT - 5 months ago

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Equillium Annual report: Q4 2025

Mar 25, 2026, 4:00 PM EDT - 5 months ago

Equillium Annual report: Q4 2025

Equillium Earnings release: Q4 2025

Mar 25, 2026, 4:00 PM EDT - 5 months ago

Equillium Earnings release: Q4 2025

Equillium to Participate in the 38th Annual Roth Conference

Mar 18, 2026, 8:30 AM EDT - 5 months ago

Equillium to Participate in the 38th Annual Roth Conference

Equillium announces $35M financing with RA Capital Management

2026-03-13T12:27:25.000Z - 5 months ago

Equillium announces $35M financing with RA Capital Management

Equillium Announces $35 Million Financing with RA Capital Management

Mar 13, 2026, 8:00 AM EDT - 5 months ago

Equillium Announces $35 Million Financing with RA Capital Management

Equillium initiated with a Buy at Roth Capital

2026-03-13T09:36:49.000Z - 5 months ago

Equillium initiated with a Buy at Roth Capital

Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference

Feb 25, 2026, 8:30 AM EST - 6 months ago

Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference

Equillium initiated with a Buy at Stifel

2026-02-24T21:49:08.000Z - 6 months ago

Equillium initiated with a Buy at Stifel

Equillium Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 12, 2026, 3:30 PM EST - 6 months ago

Equillium Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Equillium files $250M mixed securities shelf

2025-11-13T22:01:01.000Z - 9 months ago

Equillium files $250M mixed securities shelf

Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update

Nov 13, 2025, 4:05 PM EST - 9 months ago

Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update

Equillium Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Equillium Earnings release: Q3 2025

Equillium Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Equillium Quarterly report: Q3 2025

Equillium Slides: Corporate Presentation

Nov 13, 2025, 7:00 AM EST - 9 months ago

Equillium Slides: Corporate Presentation

Equillium Registration statement: Registration Filing

Nov 13, 2025, 7:00 AM EST - 9 months ago

Equillium Registration statement: Registration Filing

Equillium Transcript: KOL Event

Nov 5, 2025, 12:00 PM EST - 10 months ago

Equillium Transcript: KOL Event

Equillium Slides: KOL Event

Nov 5, 2025, 12:00 PM EST - 10 months ago

Equillium Slides: KOL Event

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025

Oct 22, 2025, 8:00 AM EDT - 10 months ago

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025

Equillium Announces Leadership and Corporate Updates

Oct 6, 2025, 4:02 PM EDT - 11 months ago

Equillium Announces Leadership and Corporate Updates

NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

Sep 23, 2025, 5:30 AM EDT - 11 months ago

NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

Equillium Registration statement: Registration Filing

Sep 9, 2025, 8:00 AM EDT - 12 months ago

Equillium Registration statement: Registration Filing

Equillium Transcript: Cantor Global Healthcare Conference 2025

Sep 5, 2025, 7:55 AM EDT - 1 year ago

Equillium Transcript: Cantor Global Healthcare Conference 2025

Equillium to Participate in the Cantor Global Healthcare Conference 2025

Aug 29, 2025, 4:03 PM EDT - 1 year ago

Equillium to Participate in the Cantor Global Healthcare Conference 2025

Equillium Quarterly report: Q2 2025

Aug 13, 2025, 6:00 PM EDT - 1 year ago

Equillium Quarterly report: Q2 2025

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

Aug 11, 2025, 8:30 AM EDT - 1 year ago

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

Equillium Slides: Corporate Presentation

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Equillium Slides: Corporate Presentation

Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy

Aug 4, 2025, 8:30 AM EDT - 1 year ago

Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy

Equillium Slides: Corporate Presentation

May 14, 2025, 7:00 AM EDT - 1 year ago

Equillium Slides: Corporate Presentation

Equillium Quarterly report: Q1 2025

May 13, 2025, 6:00 PM EDT - 1 year ago

Equillium Quarterly report: Q1 2025

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

May 6, 2025, 8:00 AM EDT - 1 year ago

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

May 1, 2025, 8:00 AM EDT - 1 year ago

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

Equillium Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Equillium Proxy statement: Proxy Filing

Equillium Announces Feedback from the U.S. Food and Drug Administration

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Equillium Announces Feedback from the U.S. Food and Drug Administration

Equillium Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Equillium Proxy statement: Proxy Filing

Equillium Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Equillium Proxy statement: Proxy Filing

Equillium Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Equillium Proxy statement: Proxy Filing

Equillium Transcript: Study Result

Mar 27, 2025, 8:30 AM EDT - 1 year ago

Equillium Transcript: Study Result

Equillium Press release: Study Result

Mar 27, 2025, 8:30 AM EDT - 1 year ago

Equillium Press release: Study Result

Equillium Slides: Study Result

Mar 27, 2025, 8:30 AM EDT - 1 year ago

Equillium Slides: Study Result

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Equillium Annual report: Q4 2024

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Equillium Annual report: Q4 2024

Equillium Earnings release: Q4 2024

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Equillium Earnings release: Q4 2024

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

Feb 6, 2025, 8:00 AM EST - 1 year ago

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Nov 13, 2024, 4:01 PM EST - 1 year ago

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Equillium Quarterly report: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Equillium Quarterly report: Q3 2024

Equillium Earnings release: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Equillium Earnings release: Q3 2024

Equillium to Present at the Stifel Healthcare Conference

Nov 13, 2024, 8:00 AM EST - 1 year ago

Equillium to Present at the Stifel Healthcare Conference

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Nov 12, 2024, 8:00 AM EST - 1 year ago

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Oct 31, 2024, 7:00 AM EDT - 1 year ago

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Equillium Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Equillium Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Equillium Transcript: 2024 Wells Fargo Healthcare Conference

Sep 5, 2024, 4:30 PM EDT - 2 years ago

Equillium Transcript: 2024 Wells Fargo Healthcare Conference

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 4, 2024, 8:00 AM EDT - 2 years ago

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

Aug 28, 2024, 8:00 AM EDT - 2 years ago

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

Aug 8, 2024, 4:01 PM EDT - 2 years ago

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

Equillium Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Equillium Quarterly report: Q2 2024

Equillium Earnings release: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Equillium Earnings release: Q2 2024

Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Aug 6, 2024, 8:00 AM EDT - 2 years ago

Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

Jul 18, 2024, 1:57 PM EDT - 2 years ago

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

Equillium Slides: Corporate Presentation

Jul 18, 2024, 12:00 AM EDT - 2 years ago

Equillium Slides: Corporate Presentation

Equillium to be included in the Russell Microcap® Index

Jun 12, 2024, 8:00 AM EDT - 2 years ago

Equillium to be included in the Russell Microcap® Index

Equillium Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 10:30 AM EDT - 2 years ago

Equillium Transcript: Jefferies 2024 Global Healthcare Conference

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

Jun 4, 2024, 8:00 AM EDT - 2 years ago

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

Equillium Slides: Study Update Presentation

Jun 4, 2024, 7:00 AM EDT - 2 years ago

Equillium Slides: Study Update Presentation

Equillium to Present at the Jefferies Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 2 years ago

Equillium to Present at the Jefferies Global Healthcare Conference

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

May 14, 2024, 8:00 AM EDT - 2 years ago

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights

May 9, 2024, 4:01 PM EDT - 2 years ago

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights

Equillium Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Equillium Quarterly report: Q1 2024

Equillium Earnings release: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Equillium Earnings release: Q1 2024

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

May 7, 2024, 8:00 AM EDT - 2 years ago

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

Equillium Proxy statement: Proxy Filing

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Equillium Proxy statement: Proxy Filing

Equillium Proxy statement: Proxy Filing

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Equillium Proxy statement: Proxy Filing

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Equillium Proxy statement: Proxy Filing

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Equillium Proxy statement: Proxy Filing

Equillium Slides: Corporate Presentation

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Equillium Slides: Corporate Presentation

Equillium Transcript: 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference 2024

Mar 28, 2024, 2:00 PM EDT - 2 years ago

Equillium Transcript: 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference 2024

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Mar 25, 2024, 4:01 PM EDT - 2 years ago

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Equillium Earnings release: Q4 2023

Mar 25, 2024, 4:00 PM EDT - 2 years ago

Equillium Earnings release: Q4 2023

Equillium Annual report: Q4 2023

Mar 25, 2024, 4:00 PM EDT - 2 years ago

Equillium Annual report: Q4 2023

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Mar 22, 2024, 8:00 AM EDT - 2 years ago

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Equillium Slides: Corporate Presentation

Feb 8, 2024, 7:00 AM EST - 2 years ago

Equillium Slides: Corporate Presentation

Equillium Slides: Corporate Presentation

Jan 8, 2024, 7:00 AM EST - 2 years ago

Equillium Slides: Corporate Presentation

Equillium Slides: Corporate Presentation

Dec 22, 2023, 7:00 AM EST - 2 years ago

Equillium Slides: Corporate Presentation

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Dec 21, 2023, 8:00 AM EST - 2 years ago

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Nov 13, 2023, 9:00 AM EST - 2 years ago

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Nov 8, 2023, 4:01 PM EST - 2 years ago

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

uieriwer
uieriwer Sep. 7 at 1:13 PM
$EQ I know everyone is expecting this to break out, but I'm getting worried it will even survive. What is latest cash flow data?
0 · Reply
LordFawkwadReturns
LordFawkwadReturns Aug. 27 at 8:53 PM
$EQ Hell yeah man doubled my position on that sweet dip
0 · Reply
AC_TRADER
AC_TRADER Aug. 27 at 8:07 PM
$EQ levels are mapped. Now let's see what price does. 👀 Built with @TrendSpider. https://share.trendspider.com/chart/EQ/7594byf17z
0 · Reply
peloswing
peloswing Aug. 27 at 3:20 PM
$EQ is up 12% since our chart @Stocktwits
2 · Reply
peloswing
peloswing Aug. 26 at 5:56 PM
$EQ up >9% already! @Stocktwits
1 · Reply
peloswing
peloswing Aug. 25 at 1:52 PM
Watch $EQ if it can break out here. Average price target is $8.60 (289% above current price). - $20 price target by Piper Sandler - $12 price target by Roth Capital
2 · Reply
peloswing
peloswing Aug. 24 at 1:29 PM
$EQ holding its long rising trendline 📊 The story: lead asset EQ504 (oral AhR modulator for ulcerative colitis) — Phase 1 proof-of-mechanism initiating mid-2026, data ~6 months later. Recent Leerink upgrade + supportive UC data drove the run. 📅 Catalyst calendar = the whole thesis: Phase 1 data readouts are the binary events. Analyst targets: $4 to $20 (avg ~$8.60)
2 · Reply
ADelightfulman
ADelightfulman Aug. 19 at 4:46 PM
$EQ in again! $MRK in the making!
1 · Reply
Orlandotrader
Orlandotrader Aug. 15 at 8:18 PM
$EQ Let’s announce that Phase One already!!
0 · Reply
Orlandotrader
Orlandotrader Aug. 15 at 8:18 PM
$EQ Trying to Form that Bottom.
0 · Reply
JeanPierreClouin
JeanPierreClouin Aug. 14 at 7:05 PM
$EQ $HIMS $SOFI I’ll buy Equillium at $1.75. Not a penny more.
2 · Reply
ADelightfulman
ADelightfulman Aug. 14 at 7:01 PM
$EQ $20 PT on a $2.00 stock! Started 1000 shares for spec play.looks promising more than $SOFI and $HIMS
0 · Reply
AceofDiamonds
AceofDiamonds Aug. 11 at 5:55 PM
$EQ Launch of Phase 1 EQ504 is imminent. 20 million will be unlocked for additional funding with many analyst upgrades.
0 · Reply
Orlandotrader
Orlandotrader Aug. 9 at 4:37 PM
$EQ Watching closely to enter. New Molecule with phase One about to commence. Some positive Brokerage coverage.
0 · Reply
LordFawkwadReturns
LordFawkwadReturns Aug. 5 at 1:24 PM
$EQ Add Zone.
0 · Reply
BanditQ
BanditQ Aug. 3 at 9:46 AM
$EQ might get back into this
1 · Reply
cubie
cubie Jul. 29 at 11:08 PM
$ORCL oh a salty oracle baggie who never have read a single cubie post lost money and is bagholding?? shocker , not. sorry not sorry🤭😂 do these tards read their own post history before talking sht?? nope, their not their bright. cubie teaches 🤭👇. and tards who trade penny stonks like $EQ whatever the fk that is = instant red flag that they dont Know sht. cubie teaches 😚😁
1 · Reply
BioTuesdays
BioTuesdays Jul. 21 at 9:04 PM
Clear Street initiated coverage of Equillium $EQ with a “buy” rating and price target of $9.00. The stock closed at $2.47 on July 20. https://biotuesdays.com/2026/07/21/clear-street-starts-equillium-at-buy-pt-9/
0 · Reply
BanditQ
BanditQ Jul. 13 at 6:03 PM
$CUE doubled my position, give me that clean chinese data. I'll use my gains for evil as always. $EQ $TENX
0 · Reply
AceofDiamonds
AceofDiamonds Jul. 13 at 12:37 PM
$EQ https://m.investing.com/news/analyst-ratings/piper-sandler-initiates-equillium-stock-with-overweight-rating-93CH-4787651?ampMode=1 EQ just received a $20.00 price target from Piper Sandler. With the impending EQ504 study and additional funds this is about the explode .
0 · Reply
BanditQ
BanditQ Jun. 30 at 7:40 PM
$TENX can't stop winning $EQ $QCLS $ZURA
2 · Reply